While cell-free DNA is our business, it’s patients who power our purpose

Steve Chapman is the chief executive officer of Natera and serves on the company’s board of directors. Chapman is a leading authority on the commercialization of genetic testing. Under his leadership, Natera has launched 20 products that have transformed patient care, including two of the fastest growing genetic tests of all time. The company’s suite of products includes the Signatera™ oncology test for molecular residual disease, the Prospera™ transplant assessment test, the Renasight™ kidney gene panel which screens for genetic causes of chronic kidney disease, and the highly differentiated Panorama™ test serving patients in the non-invasive prenatal testing market.

Before his appointment as CEO in 2019, Chapman held a number of other leadership positions at Natera including chief operating officer. Earlier in his career, he worked at Genzyme Genetics. He began his career as a researcher in the department of human genetics at the University of California Los Angeles (UCLA), where he designed arrays identifying SNPs associated with multiple sclerosis.

Chapman serves on the board of directors of the American Clinical Laboratories Association (ACLA). In 2024 and 2025, he was named one of the top healthcare technology CEOs by Healthcare Technology Report, and was named BioTechnology Innovator of the Year by BioTech Breakthrough in 2024. He has been a guest on CNBC and other shows and podcasts to share more about Natera’s impact on patient care in the field of personalized genetic testing and diagnostics. He has also authored multiple scientific papers.

Chapman holds a bachelor’s degree in microbiology, immunology, and molecular genetics from UCLA, where he graduated with honors.

Mike Brophy, MBA, is Natera’s chief financial officer. He joined the company in 2015 and has served in a number of leadership roles during his tenure, including vice president of corporate development and investor relations, and senior vice president of finance and investor relations.

Prior to joining Natera, Brophy served as a vice president and executive director in the investment banking division of Morgan Stanley, where he focused on advising corporate clients in the life science tools and diagnostics sector. His military career included leading a multi-agency, 10-person team on a $1.4 billion contract to modernize 10 remote satellite tracking stations worldwide.

Brophy holds a bachelor’s degree in economics from the United States Air Force Academy and an MBA from UCLA.

Alexey Aleshin, M.D., MBA, serves as chief medical officer & general manager of oncology and early cancer detection at Natera. He joined the company in 2017 and has served in many leadership capacities during his tenure, including medical director of oncology, vice president of oncology medical affairs, and chief medical officer.

Aleshin has a demonstrated history of working in the biotechnology industry, with a focus on circulating biomarkers and novel clinical trial design and execution. He is an experienced product strategist and cross-functional team manager. Earlier in his career, he served as an advisor and consultant for various companies focused on advancing clinical adoption of next-generation sequencing technologies.

Aleshin holds an M.D. and an MBA from UCLA. He completed his internal medicine residency at Stanford University Medical Center and his hematology/oncology fellowship at Stanford Hospital.

Olesya Anisimova, CPA, has served in public accounting and industry for over 15 years. During her career, Anisimova’s primary focus was on manufacturing and biotechnology industries. She came from Ernst & Young and started at Natera in February 2015 as an assistant controller. She was subsequently promoted to senior director of finance and corporate controller. Anisimova’s role evolved into vice president of finance and senior vice president of finance. Since January 2022, Anisimova has served as Natera’s chief accounting officer.

Since joining the company, Anisimova has played a crucial role in the company’s success. She successfully filed Natera’s IPO with the accounting and finance team and is responsible for Natera’s annual and quarterly SEC filings. She has managed a broad range of responsibilities including driving improvements in various operations, performing SEC filings and SOX compliance controls.

Jake Chabon, Ph.D., joined Natera in 2025 as senior vice president & general manager of its hematology franchise. He co-founded Foresight Diagnostics and served as its chief executive officer and chief scientific officer until its acquisition by Natera in 2025. Under his leadership, Foresight raised $86 million in venture funding and built partnerships with more than 25 academic medical centers and pharmaceutical companies.

A molecular biologist and bioinformatics scientist, Chabon has authored more than 50 peer-reviewed publications with more than 9,000 citations. Prior to founding Foresight, his research focused on developing novel noninvasive cancer detection methods for the early detection of cancer and to study treatment response and resistance. He has been recognized as a 2024 EY Entrepreneur of the Year finalist and a 2023 Dealmakers Award honoree.

Chabon completed his Ph.D. and postdoctoral training at Stanford University under the mentorship of Maximilian Diehn, M.D., Ph.D., and Ash Alizadeh, M.D., Ph.D., with whom he co-founded Foresight Diagnostics in 2020.

Jerry Diffley, MBA, joined Natera in August 2017 as its chief compliance & privacy officer. He is a seasoned laboratory executive with extensive experience in U.S. and international laboratory compliance, privacy, billing, and laboratory operations.

Prior to joining Natera, Diffley worked at Quest Diagnostics in a variety of operational positions, as well as legal compliance. He is certified as a compliance professional and has experience with global compliance organizations, global healthcare, General Data Protection Regulation, privacy, and data security. He has developed corporate-wide compliance programs and lobbied for the healthcare industry at different levels of government.

Diffley holds a bachelor’s degree in education from SUNY Plattsburgh and an MBA in healthcare administration from Stony Brook University.

Eric Evans, Ph.D., joined Natera in 2020 as chief scientific officer. Prior to joining Natera, he was co-founder and chief scientific officer of Counsyl for 12 years. In that role, he led R&D and clinical operations for a molecular diagnostics portfolio in women’s health and oncology. He has authored papers in reproductive genetics and molecular diagnostics, including journals such as JAMA, Genetics in Medicine, Clinical Chemistry, and Prenatal Diagnosis.

He received a B.S. in biological sciences from the University of Delaware and a Ph.D. in genetics from Stanford University. While at Stanford, he was a Stanford Graduate Fellow working on the genetics of aging and the immune system.

John Fesko, MBA, serves as president & chief business officer of Natera. He leads companywide efforts across multiple functions and programs, including collaborations with payors, government affairs, business development, market development, pharmaceutical services, patient experience, communications, marketing, and international commercial operations and strategy.

Before joining Natera in 2014, Fesko worked at Roche, Novartis Pharma AG, MPM Capital, and InVivoScribe. He has extensive experience in business development, strategic planning, and product management.

Fesko holds a bachelor’s degree in biochemistry and economics from the University of Notre Dame and an MBA from MIT.

Phil Grinnell, MBA, is the chief sales officer at Natera, where he oversees the strategy and continued growth of the sales organization across the company. In this role, he leads the U.S. sales teams across women’s health, oncology, and organ health, along with sales training and commercial analytics.

During Grinnell’s tenure at Natera, he has held a number of additional leadership positions, including senior vice president of sales and senior director of sales operations. He joined the company in 2011 as a regional sales director.

Earlier in his career, Grinnell spent five years with Athena Diagnostics, where he gained experience in genetic diagnostic testing in both direct sales and sales leadership.

Grinnell holds an MBA from Villanova University and a B.S. from the University of Texas at Austin. He currently serves as president of the board of directors of the Kaiserman Jewish Community Center.

Ramesh Hariharan, Ph.D., MBA, serves as the general manager of Natera’s women’s health business. He joined Natera in 2016 to head marketing and medical education, and later transitioned to his current role.

Hariharan’s career spans a range of subspecialties including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs and a novel process for agglomerating nanoparticles. He also worked at McKinsey, where he served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K. He has supported a wide range of activities, such as product launches, market expansion, life cycle strategies, and business turnarounds.

Hariharan has also held marketing leadership positions in oncology, women’s health, and vaccines at Novartis, Abbott/AbbVie, and Biotheranostics.

Hariharan holds a bachelor’s degree in chemical engineering from IIT Bombay, an MBA from MIT Sloan School of Management, and a doctorate in chemical engineering from Princeton University.

Rishi Kacker serves as Natera’s chief technology officer, bringing 20 years of experience in software, genetics, and health tech entrepreneurship. At Natera, he is responsible for leading a team including product, UX, software engineering, and IT, with the mission to expand access to genetic testing for millions each year through innovations and transformation in the patient and provider experience. Additionally, he has led an extensive clinico-genomic data and research platform being used to accelerate Natera’s knowledge of genetic disease.

Prior to Natera, Kacker was the chief technology officer at Myriad Genetics and co-founder and senior vice president of technology at Counsyl (acquired by Myriad Genetics). He started his career as co-founder of Voltage Security, a data security and enterprise software business that was acquired by HP Enterprise.

Kacker holds a B.S. in computer science from Stanford University.

As senior vice president of laboratory affairs & executive laboratory director, Dianne Keen-Kim, Ph.D., FACMG, HCLD (ABB), is responsible for the overall operation and administration of the clinical laboratories, as well as Natera’s quality culture.

Since joining Natera in 2018, Keen-Kim built the genetic variant classification and curation processes, has grown data analysis and clinical reporting operations, and provided daily quality oversight and risk management in oncology, women’s health, and transplant diagnostics.

With expertise in cell-free DNA, next-generation sequencing, and automation technologies, Keen-Kim earned a bachelor’s degree from Carnegie Mellon University, a Ph.D. from MIT, completed her fellowship at UCLA, and currently serves as an adjunct clinical professor at Stanford University School of Medicine.

Keen-Kim is licensed in California and New York to direct medical laboratories and maintains three HHS-approved board certifications. She is a mentor and champion for women leaders, and is passionate about staff training and development to create growth opportunities for the next generation.

Chitra Kotwaliwale, Ph.D., serves as chief product officer at Natera. She joined the company in 2019 and has held multiple roles across product management and strategy, overseeing product management for the women’s health team, managing overall strategic planning, project management for engineering and R&D, and coordinating global product strategy.

Prior to joining Natera, Kotwaliwale served as director of product marketing at Agilent Technologies, where she managed the company’s product management team responsible for target enrichment content products for rare diseases and oncology. She previously served as senior product manager of sequencing at Complete Genomics and, prior to that, as a computational biologist at Adaptive Biotechnologies (formerly Squenta, Inc.).

Kotwaliwale holds a bachelor’s degree in biology from the College of Wooster and a doctorate in molecular and cell biology from the University of Washington and the Fred Hutchinson Cancer Center. She completed her post-doctoral fellowships at the University of California, Berkeley, which was funded by prestigious fellowships from the Damon Runyon Cancer Research Foundation and Howard Hughes Medical Institute.

Eric Matthews, MBA, MPP, joined Natera as general manager of biopharma in December 2025. Prior to joining Natera, Matthews was senior vice president and chief business officer at Caris Life Sciences, where he rapidly scaled a portfolio of Dx, data, and discovery partnerships.

Matthews’ leadership roles in biopharma include chief commercial officer of Arcus Biosciences, head of IO global marketing at AstraZeneca, and lifecycle leader at Roche/Genentech. Through his 25 years in biopharma, bringing nine new medicines to market across 19 indication launches, Matthews has developed a track record of excellence in leading organizations, forging strategic partnerships and transforming the standard of care for patients.

Matthews holds dual master’s degrees from Duke University (MBA, MPP – Healthcare Innovation), as well as dual Bachelor of Science degrees from Duke University in molecular biology and economics.

Solomon Moshkevich, MBA, serves as president of clinical diagnostics at Natera, where he oversees productization, clinical validation, commercialization, and quality across the company.

Since joining Natera in 2011, Moshkevich has built and led multiple teams, including global marketing, product management, medical and scientific affairs, commercial operations, clinical trial operations, business development, international sales, program management, and portfolio strategy. He has played a leading role in the development, clinical validation, and commercial success of all of Natera’s cell-free DNA products including Panorama™, Prospera™, and Signatera™. Most recently, Moshkevich served as general manager of oncology for the company, overseeing a period of tremendous growth and leading the company’s efforts to achieve Medicare coverage for Signatera across multiple cancer types.

Moshkevich began his career as a consultant with Bain & Company before joining the private equity investment team at Parthenon Capital. He graduated from Columbia University summa cum laude with a bachelor’s degree in economics and mathematics, and holds an MBA from Stanford University. He currently serves on the board of directors of the Ronald McDonald House Charities of the Bay Area.

Sheetal Parmar, M.S., CGC, serves as senior vice president of medical affairs for women’s health at Natera. She is a board-certified genetic counselor specializing in prenatal diagnosis and screening.

Since joining Natera in 2013, Parmar has held a number of positions, including senior director of clinical genetic services and director of medical education. Before joining the company, she worked for 11 years as the lead prenatal genetic counselor at a high-risk prenatal diagnosis clinic and cytogenetic laboratory.

Parmar serves on the board of directors of the National Society of Genetic Counselors (NSGC). In 2020, she accepted the Leading Women Entrepreneur Force for Change Illuminator Award for her leadership and contributions to Natera’s positive impact on the lives of others during the COVID-19 pandemic.

Parmar holds a bachelor’s degree in molecular and cell biology from UC Berkeley and a master’s degree in genetic counseling from the University of Cincinnati, where she was an Albert C. Yates Scholar and Fellow.

Daniel Rabinowitz, LLM, is secretary & chief legal officer at Natera. Prior to joining Natera, he was a corporate partner at the law firm McDermott, Will & Emery, and before that, was a corporate lawyer at the law firm Davis Polk & Wardwell. He has worked in the United States and Europe, advising domestic, foreign, public, and private companies on capital raisings, M&A, investment management, and compliance with U.S. federal and state securities law.

Rabinowitz holds a bachelor’s degree and an LLB degree from the University of the Witwatersrand, South Africa, graduating at the top of his law school class. He holds an LLM degree from New York University School of Law with both Rotary Foundation and Fulbright Scholarships. He studied genetics, biochemistry, and molecular biology at Harvard University Extension School. Admitted in New York only.

Matthew Rabinowitz, Ph.D., is co-founder of Natera and currently serves as the executive chairman of its board of directors. From 2005 to 2019, he served as Natera’s chief executive officer.

Rabinowitz serves as a chairman, director, and/or advisor to many companies and nonprofits involved in diagnostics, biotech, artificial intelligence (AI), health services, and nature conservation. Additionally, he manages an early stage technology venture fund focused on biotech, security, and AI.

Companies Rabinowitz has founded have twice received the World Economic Forum Technology Pioneer award and thrice received Edison Awards in the United States. He has served as consulting professor in Aeronautics and Astronautics at Stanford, as visiting faculty in Genetics at Harvard, and has received the Scott Helt Award from the Institute of Electrical and Electronics Engineers.

Rabinowitz has authored well over 100 patents and publications respectively, including papers in the top reproductive, transplant, and oncology journals. He led the development of the highest-volume clinical genetic test in U.S. history, which transformed pregnancy management, and oversaw the development of a technology that tracks tumor mutations in blood that has reshaped cancer management and received multiple FDA breakthrough designations. He also led the first whole-genome polygenic modelling of embryos to prevent conferring disease risks to our children, as well as other breakthrough products. In 2024, Rabinowitz was named R&D Leader of the Year by R&D World.

Rabinowitz studied electrical engineering and physics at Stanford University. He received the Levin and Terman awards, the top academic awards offered by each department, and a graduate fellowship to the school of engineering, where he completed his doctorate in electrical engineering.

Meredith Reichert, Ph.D., serves as the senior vice president of commercial for emerging business at Natera.

Reichert brings more than 15 years of experience at the intersection of diagnostics, life sciences, and precision medicine. Before joining Natera, Reichert was the chief commercial officer at Karius, an infectious disease diagnostics company using circulating microbial cell-free DNA to assist physicians in making rapid treatment decisions. Before that, Reichert was an associate partner at McKinsey & Company, specializing in the healthcare practice where she developed growth strategies for precision medicine companies, steered clinical and partnership strategies with national healthcare providers, and devised successful market-entry approaches for both diagnostic and therapeutic products.

Reichert holds a Ph.D. in neurobiology and a B.S. in biochemistry and molecular biology.

John Ryan, Ph.D., MBA, joined Natera as its chief laboratory officer in 2023. He brings more than 28 years of operations experience, with expertise in diagnostic laboratory operations, laboratory partnerships, supply chain management, kit manufacturing, and customer service.

Ryan most recently served as senior vice president of operations at Myriad Genetics, overseeing neuroscience, women’s health, oncology, and international operations. At Myriad, he also served as vice president of hereditary cancer operations, senior director of customer service, and senior director of operations. Prior to that, he served in the Armed Forces DNA Identification Laboratory.

Ryan holds a bachelor’s degree in biochemistry and molecular biology from the University of California, Santa Cruz, an executive MBA from the University of Utah David Eccles School of Business, and a doctorate in genetics from Stony Brook University.

James Stover, Ph.D., joined Natera in 2025 as general manager of health systems, where he leads the integration of genomic testing, population health, and AI-powered clinical decision support into large U.S. health systems. In this role, he oversees product strategy, commercialization, health system partnerships, and the development of new precision medicine platforms that support risk stratification, early disease detection, and improved clinical outcomes at scale.

Previously, Stover served as chief business development officer at Nashville Biosciences, where he played a central role in launching the company from Vanderbilt University Medical Center. He led the development of the company’s product and commercial strategy, and was instrumental in establishing the Alliance for Genomic Discovery, a nine-figure strategic partnership with leading pharmaceutical companies, supporting one of the fastest and most diverse whole-genome sequencing programs globally.

Stover also led corporate and business development at Aegis Sciences Corporation following the acquisition of Diagnovus, a venture-backed molecular diagnostics company he co-founded. Under his leadership, Diagnovus launched five novel clinical laboratory tests and secured multiple biopharma partnerships. He has also held positions at The Scripps Research Institute, Square 1 Bank, and Warburg Pincus.

Stover earned a bachelor’s degree in biochemistry from the University of Virginia (cum laude) and a Ph.D. in chemistry from Vanderbilt University (summa cum laude), where he was a National Institutes of Health Fellow. He received the Tibbetts Award from the U.S. Small Business Administration for impact on the SBIR/STTR programs and is currently a member of the U.S. Men’s Senior National Soccer Team.

Bernie Tobin, MBA, is responsible for strategy and execution for Natera’s organ health products. Tobin is a >25-year veteran of the healthcare industry. Before joining Natera, he served as president of Crescendo Bioscience, a wholly owned subsidiary of Myriad Genetics. Crescendo focused on using proteomics to deliver precision medicine to patients with autoimmune disorders.

Previously, Tobin held several senior-level positions at Amgen, including general manager of both the Netherlands and Brazil, and global head of commercial excellence. In addition, he led the global integration of a business development acquisition in over 100 countries. Prior to that, Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Company.

Tobin received a B.S. in public service and administration from Iowa State University and an MBA from the Fuqua School of Business at Duke University.